step 3 semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase trial STEP 3: Weekly semaglutide results

scrambled: 41.1 1.4 vs

Robertson JC, Watson JT, Kelley DB

Tesamorelin stands out with a robust clinical corpus including pivotal phase 3 trials on over 800 patients (HIV lipodystrophy indication), with 52-week data documenting a significant reduction in visceral fat (visceral adipose tissue, VAT) and improved lipid parameters

Mistake 1: not eating enough This sounds counterintuitive for a weight loss medication, but under-eating is one of the most common and most damaging mistakes

Other interactions may exist

Its something I think we as clinicians need to educate our patients about especially females of childbearing age